Gene modified T cell therapy for patients with cancer

Heczey András
Section Pediatric Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

T cells genetically modifi ed to express chimeric antigen receptors can combine the antigen specificity of monoclonal antibodies with the cytotoxic function, active biodistribution and long term persistence of T cells. The approach can induce 90% complete remission rate in patients with CD19+ lymphoid leukemias; however, the in patients with solid tumors the antitumor effi cacy of CAR T cells have not reached similar levels yet. The increased levels of interleukin-6 due to T cell activation play key roles in the majority of side effects and using anti-IL-6 monoclonal antibody, tocilizumab can effectively treat these complications. Novel gene modifi cation strategies and improvements in CAR T cell manufacturing, the approach has the potential to fundamentally change the way patients with cancer are treated in the not too distant future.


Kapcsolódó cikkek

MKOT 2017. Minden jog fenntartva. Website by Ranlom